Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US.

The first copycat Lantus – Eli Lilly/Boehringer Ingelheim's Basaglar – was approved in the US in 2017, but that was approved as under a new drug application, not as a biosimilar, and so also ...

TMUBMUSD03M | A complete U.S. 3 Month Treasury Bill bond overview by MarketWatch. View the latest bond prices, bond market news and bond rates.